TARS Tarsus Pharmaceuticals, Inc.
Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Tarsus Pharmaceuticals, Inc. (TARS) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New cybersecurity risk: increased threat from geopolitical tensions, including Russia-Ukraine conflict and Middle East unrest potentially disrupting IT systems
- • Most updated risk: net loss narrowed to $12.6M Q3 2025 vs $23.4M Q3 2024, deficit grew to $418.3M as of Sept 30, 2025 reflecting ongoing operating losses
Quarterly Financial SummaryXBRL
Revenue
$119M
▲ +146.7% YoY▲ +15.6% QoQ
Net Income
-$13M
▲ +46.3% YoY▲ +38.1% QoQ
Operating Margin
-12.2%
▲ +4005bp YoY▲ +937bp QoQ
Net Margin
-10.6%
▲ +3807bp YoY▲ +921bp QoQ
ROE
-3.8%
Total Assets
$535M
EPS (Diluted)
$-0.29
▲ +50.8% YoY▲ +38.3% QoQ
Operating Cash Flow
$18M
▲ +311.0% YoY▲ +162.1% QoQ
Source: XBRL data from Tarsus Pharmaceuticals, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tarsus Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.